Taiho Ventures, LLC
Preclinical to proof of concept.
Syndicate capital and operating partners for first-in-class therapeutics in oncology, immunology, and urology.
We invest where the science is ready to be tested in patients.
Pre-IND through proof of concept. Oncology, immunology, urology. First-in-class molecules or new biology — not "me-too" programs targeting the same receptor with a different linker.
We syndicate, we operate, and where the asset earns it we underwrite a build-to-buy structure with our corporate parent — the same kind that built Cullinan Pearl from white paper through a Pfizer acquisition.
Twenty-three syndicate investments. Five clinical-stage assets. Four realized exits.
Cullinan Pearl
Oncology · Phase II · Bispecific Ab
Re-acquired by Taiho · 2023
Arcus Biosciences
Oncology · Phase III · Small molecule
NYSE: RCUS
Orna Therapeutics
Platform · Preclinical · Circular RNA
Merck partnership · 2023
Harpoon Therapeutics
Oncology · Phase I/II · T-cell engager
Acquired by Merck · 2024
Build · Hold · Re-acquire
We led the build of Cullinan Pearl. We re-acquired it when the science was ready. Most of the work happened in the years between.
On Cullinan Pearl — Taiho Ventures × Cullinan Oncology, 2017–2024
Image Slot
1600×1000 · 8:5
/07-cinematic-dark-syndicate/cullinan-pearl.jpg
Editorial photo: Cullinan Pearl lab, team, or asset. Real, not stock.
- Initial check
- $8M · 2017 Series A lead
- Re-acquisition
- Taiho · 2023
- Stage at exit
- Phase II · zenocutuzumab